J9集团

Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.

Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

J9集团为德睿智药自主研发的GLP-1RA幼分子口服药物MDR-001提供了原料药工艺开发和造剂研发服务，助力其研发提快。

祝贺拓领博泰TollB-001片获FDA临床试验核准！这是拓领博泰团队近二十年的免疫调控机理钻研和免疫调控药物钻研的厚积薄发，也是J9集团药学钻研CDMO服务平台的又一次成功经验积淀。

J9集团将持续拓展眼科药物领域的创新技术，助力更多眼科药物跑出研发“加快率”！

J9集团助力GT919实现了其从药物发现到临床申报，蕴含药物发现、药学钻延注临床前钻研等一站式临床前钻研服务

J9集团祝贺轩竹生物齐全敲除岩藻糖的双抗ADC药物KM501获批临床！J9集团切合GLP规范的临床前钻研服务再添成功案例！

祝贺柯菲平！J9集团为凯普拉生的研发提供了从化合物设计到临床前候选化合物，以及大部门体表 H+K+-ATPase测试等服务，助力其成功获批。